晚期恶性肿瘤患者凝血功能异常的检测和意义

目的探讨晚期肺癌、胃癌和结肠癌患者的凝血酶原时间（PT）、部分凝血活酶时间（APTT）、纤维蛋白原（FDP）、血小板计数（PLT）和D-二聚体含量的变化和意义。方法采用血常规检测仪和BE凝血仪检测检测患者的PLT、PT、APTT和FDP，采用ELISA法检测D-二聚体含量，并以健康体检者作为对照。结果晚期肺癌、胃癌和结肠癌患者胛、APTT、FDP较健康对照者延长，D-二聚体含量升高，差异有显著性（P〈0．05），而PLT计数无明显变化。结论晚期肺癌、胃癌和结肠癌患者存在凝血功能异常，应加强检测，预防出血等并发症的发生。

Study of hemostatic alterations in patients with advanced cancer

Objective To investigate the clinical significance of the changes of plasma hemostatic markers （ PT, APTr, FDP, PLT and D-dimer） concentrations in patients with lung cancer, gastric cancer and colorectal cancer. Methods In 52 patients with advanced cancers, hemostatic function markers were evaluated with blood routine detector and BE coagulation instrument, including PT, APTT, FDP, PLT. D-dimer was detected with ELISA method. A group of healthy volunteers was taken as controls. Results It was found that the levels of PT, APTT, FDP and D-dimer significantly increased in the patients with advanced carcinoma patients, while PLT count did not change significantly. Conclusion The hemostatic function of advanced carcinoma patients is abnormal and should be monitored to prevent the complication of hemorrhage.